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regression analysis showed an interesting, but not 
statistically significant trend: better pathological responses 
were seen in patients presenting more important reduction of 
SUVmax and SUVmean (Fig. 1). 
 
 
Conclusions: These preliminary prospective data seem to 
support the hypothesis that changes of some 18FDG-PET/CT 
values, as SUVmax and SUVmean, could predict the pathological 
response in locally advanced rectal cancer after neoadjuvant 
treatments. Further analyses are needed. 
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Purpose/Objective: To report the 4-year outcomes of a 
consecutive prospective series of anal cancer patients 
treated with concurrent chemo-radiation delivered with 
intensity-modulated radiotherapy (IM-RT), employing a 
simultaneous integrated boost (SIB) approach. 
Materials and Methods: A prospective series of 54 patients 
was enrolled between 2007 and 2013. Treatment schedule 
consisted of 50.4 Gy/28 fractions (1.8 Gy daily) to the gross 
tumor volume, while the elective nodal volumes were 
prescribed 42 Gy/28 fractions (1.5 Gy/daily) for patients 
having a cT2N0 disease. Patients with cT3-T4/N0-N3 tumors 
were prescribed 54 (T3) or 59.4 (T4) Gy/30 fractions (1.8 Gy 
daily) to the gross tumor volume; gross nodal volumes were 
prescribed 50.4 Gy/30 fr (1.68 Gy daily) if sized < 3 cm or 54 
Gy/30 fr (1.8 Gy daily) if > 3 cm; elective nodal regions were 
given 45 Gy/30 fractions (1.5 Gy daily). Chemotherapy was 
administred concurrently according to the Nigro’s regimen. 
Primary endpoints was colostomy-free survival (CFS). 
Secondary end-points were local control (LC), disease-free 
survival (DFS), cancer-specific survival (CSS), overall survival 
(OS) and toxicity profile. 
Results: Median follow up was 32.6 months (range 12-84). 
The actuarial probability of being alive at 4 years without a 
colostomy (CFS) was 68.9 % (95% CI: 50.3-84.7%). Actuarial 4-
year OS, CSS, DFS and LC were 77.7% (95% CI: 60.7-88.1%), 
81.5% (95% CI: 64-91%), 65.5% (95% CI: 47.7-78.5%) and 84.6% 
(95% CI: 71.6-92%). Actuarial 4-year metastasis-free survival 
was 74.4% (95% CI: 55.5-86.2%). Maximum detected acute 
toxicities were as follows: dermatologic – G3: 13%; GI-G3: 8%; 
GU-G3: 2%; anemia-G3: 2%; neutropenia-G3:11%; G4: 2%; 
thrombocytopenia- G3:2%. Four-year G2 chronic toxicity rates 
were 2.5% (95% CI: 3.6-16.4) for GU, 14.4% (95% CI: 7.1-28) 
for GI, 3.9% (95% CI: 1-14.5%) for skin and 4.2% (95% CI: 1.1-
15.9) for genitalia.  
Conclusions: Our findings support the feasibility of IMRT in 
the combined modality treatment of anal cancer, with 
comparable results to the literature with respect to local 
control, spinchter preservation and survival. Acute toxicity is 
lower if compared to series employing standard techniques. 
Our results support the use of IMRT on a routine basis for the 
treatment of anal cancer. 
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Purpose/Objective: To analyze results of combined 
treatment of adjuvant radio-chemotherapy in patients 
diagnosed with gall-bladder cancer after complete resection. 
Materials and Methods: Since June 1993 until March 2013, 87 
patients with the diagnosis of gallbladder cancer who 
underwent extended or simple cholecystectomy and were 
staged as T1b-2-3N0-1M0, received adjuvant radio-
chemotherapy at Instituto Oncológico, Viña del Mar. Overall 
survival and median survival were analyzed in relation to 
different prognostic factors, using Kaplan-Meier techniques 
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and compared with log-rank tests.Since June 1993 until 
March 2013, 87 patients with the diagnosis of gallbladder 
cancer who underwent extended or simple cholecystectomy 
and were staged as T1b-2-3N0-1M0, received adjuvant radio-
chemotherapy at Instituto Oncológico, Viña del Mar. Overall 
survival and median survival were analyzed in relation to 
different prognostic factors, using Kaplan-Meier techniques 
and compared with log-rank tests. 
Results: With a median follow-up of 43 months (range: 5-180 
months) the 5 and 10-year overall survival (OS) rate for the 
entire cohort was 44.9% and 36.8%, respectively, and the 
median survival time was 45 months. In the group who 
underwent extended cholecystectomy, the 5-year OS was 
57.2% versus 31.2% for those who underwent simple 
cholecystectomy (p=0.032). The median survival time was 57 
and 27 months for patients with extended cholecystectomy 
and simple cholecystectomy, respectively (p=0.032).  
Conclusions: After a complete resection, radio-
chemotherapy appears a good approach and can achieve a 
long term survival rate. This benefit is higher for those in 
which surgery is an extended cholecystectomy.  
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Purpose/Objective: A clinical data registry was required to 
support the data requirements of the UK patients undergoing 
rectal brachytherapy. The data input and access 
requirements for this group culminated in the need for a 
bespoke development rather than an off-the-shelf product. 
These extended requirements included the need to allow 
patient-led data entry, multi-centre access, discussion 
forums, customised data extraction and visualisation. 
Materials and Methods: A bespoke, extendable and 
customisable web-based clinical data repository system was 
developed. Case report forms were translated into web-
enabled forms either by a specially implemented form 
designer or via consultation with the developer. Patient-led 
data entry is achieved by allowing data managers to assign 
each case a patient login. Patients are able to enter data on 
baseline and follow-up assessments via a simple web 
interface or tablet App before or during consultation. The 
registry has been designed to allow multi-centre data input 
while allowing doctors from disparate centres to be given 
permission to view other centres cases. Security of data is 
ensured by separation of the web server from the data 
server, secure certificates and user accounts with group 
assignments. All events that occur on the registry are logged 
in encrypted tables allowing audit trails to be tracked. 
Results: An extendible web-enabled database has been 
developed which allows a bespoke and advanced data 
registry to be developed and deployed relatively rapidly. A 
unique feature of this registry system is patient-led data 
entry. Patients are reminded by email to enter data shortly 
before follow-up appointments and are able to utilise the 
web interface or tablet Apps. Additionally, a focus has been 
placed on the ability to extract customised data reports and 
visualisation reports without the need for statistical 
packages. This feature allows varying questions to be asked 
of the registry directly via the web interface. 
Conclusions: Existing clinical trial and clinical registry 
systems have been evaluated for suitability for this trial. 
Some of the systems evaluated were more oriented to clinical 
trial management than needed for the current requirements 
and others were restricted in the patient-led data entry and 
data visualisation. These finding led to the development of a 
customisable data registry system, which is able to support 
multiple clinical registries and requirements. New registries 
can be set-up with relative simplicity by utilising built-in 
form and report designers tools. Patient-led entry enables a 
greater emphasis to be placed on survivorship which is very 
important in this patient-centred treatment approach. 
With thanks to BRIGHT charity for initial funding support. 
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Purpose/Objective: While for locally-advanced (T3-T4) 
tumors, the combination of elective lymph-node irradiation 
along with concomitant chemotherapy (CT) has been 
demonstrated to improve loco-regional control (LRC) 
compared to radiotherapy (RT) alone, the best treatment 
strategy remains controversial in early-stage anal tumors (T1-
T2) without nodal involvement. The role of prophylactic 
inguinal irradiation (PII) in this setting remains an open issue, 
especially in the era of modern EBRT techniques. The aim of 
this study was to assess outcomes and toxicity results of 
highly-conformal EBRT techniques in patients with early-
stage T1-2 N0 anal cancers measuring < 3 cm and involving < 
50% of the anal circumference treated conservatively with or 
without concomitant CT. 
Materials and Methods: Data of 44 patients with cT1 (n=13) 
or cT2 <3 cm, involving < 50% of the anal circumference (n= 
31, median size 2.5 cm) cN0, histologically proven anal 
carcinoma, treated in two institutions between 03/2006 and 
04/2014 were retrospectively reviewed. Median age was 61 
years (range: 36-87). For all patients, the pelvis and inguinal 
region were treated with highly conformal EBRT techniques, 
including helical Tomotherapy, intensity-modulated radiation 
therapy (IMRT) or volumetric modulated arc therapy (VMAT) 
in 22, 17 and 5 patients, respectively. Regarding the boost, 
28 patients were treated with 3D-conformal RT, 6 with 
Tomotherapy, 4 with IMRT and 6 with VMAT. Image-guided RT 
modalities were used for daily repositioning. EBRT schedule 
consisted of elective lymph node irradiation including PII to 
36 Gy (1.8 Gy/fraction), followed by a boost to the GTV up to 
59.4 Gy after a median gap of 10 days (range: 1-26). 
Concomitant CT was delivered in 37 patients (Mitomycin/5-
FU and Mitomycin/Capecitabine for 25 and 9 patients, 
respectively). Toxicity was scored according to the CTCAE 
v3.0 scale. 
Results: Treatments were delivered in all patients as 
planned, with no interruptions. After a median follow-up of 
